Published September 8, 2023

Common Cold Market Report Overview:                 

Report Attribute


Base Year


Forecast Years


Historical Years


Market Growth (2023-2033)


The report offers a comprehensive analysis of the common cold market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the common cold market.

Request for a Sample Copy of this Report:

The 7 major common cold markets are expected to exhibit a CAGR of 4.55% during 2023-2033. The escalating instances of viral respiratory infections caused by rhinoviruses, respiratory syncytial viruses, influenza viruses, parainfluenza viruses, and enteroviruses, among others, is the prime factor impelling market growth. Besides this, the rising prevalence of numerous associated risk factors, such as weakened immune systems, close contact with infected individuals, and exposure to cold weather conditions, is acting as another significant growth-inducing factor. Moreover, the widespread application of decongestants for easing nasal congestion and pain relievers for alleviating headaches, sore throats, and body aches is positively impacting the market growth.

Additionally, the increasing use of saline nasal sprays, which assist in moisturizing and clearing nasal passages to reduce congestion and improve breathing, is aiding in market expansion. Furthermore, the growing utilization of molecular diagnostic tests such as polymerase chain reaction (PCR) and nucleic acid amplification techniques, which aid in identifying specific viral ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) sequences in respiratory samples, are strengthening market growth. 

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the common cold market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the common cold market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current common cold marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance

Competitive Landscape With Key Players:

The competitive landscape of the common cold market has been studied in the report with the detailed profiles of the key players operating in the market.

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures:

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Other Related Reports: 

necrotizing enterocolitis market

pneumonia market

generalized pustular psoriasis market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Media Contact:

Company Name: IMARC Group

Contact Person: Elena Anderson

Email: [email protected]

Phone: +1-631-791-1145

Address: 134 N 4th St

City: Brooklyn

State: NY

Country: United States


Source link